Previous 10 | Next 10 |
2023-10-24 08:23:16 ET Losers: INVO Bioscience ( INVO ) -19% . Markforged Holding Corporation ( MKFG ) -18 % schedules third Quarter 2023 earnings announcement ; provides preliminary third Quarter results and updates 2023 revenue guidance. IonQ ( IONQ...
View the video: https://youtu.be/23WqSM9gI40 CEL-SCI Corporation (NYSE American: CVM) today released a video presentation in which the Company’s CEO, Geert Kersten, shares the most recent data presented at the European Society for Medical Oncology (ESMO) Congres...
2023-10-23 15:35:21 ET More on Cel-Sci Seeking Alpha’s Quant Rating on Cel-Sci Historical earnings data for Cel-Sci Financial information for Cel-Sci For further details see: CEL-SCI climbs after ESMO data for lead asset Multikine
2023-10-23 13:18:40 ET Gainers: LumiraDx Limited ( LMDX ) +186% . Akumin ( AKU ) +178% . Textainer Group Holdings Limited ( TGH ) +44% . Cel-Sci Corp. ( CVM ) +41% . ImmunoPrecise Antibodies Ltd ( IPA ) +27% . Soluna Holdings...
2023-10-23 12:19:40 ET DENVER, Colo., Oct. 23, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; LumiraDx Ltd (NASDAQ: LMDX), CEL-SCI Corp (AMEX: CVM), Inpixon (NASDAQ: INPX), INVO Bioscience Inc (NA...
Target patient population for regulatory submissions finalized: Patients with low PD-L1 , in contrast to current checkpoint inhibitors which work best with high PD-L1. Addressing unmet need in ~145,000 head and neck cancer patients per year worldwide. Routine cancer sc...
Achieves significant milestones toward commissioning of manufacturing facility in preparation for Biologics License Application for regulatory approval submissions CEL-SCI Corporation (NYSE American: CVM) today reported that its Multikine* (Leukocyte Interleukin, Injection) cGMP s...
CEL-SCI will present the MHRA with new results that demonstrate pre-surgical response rates and overall survival advantages that are superior to those published by CEL-SCI previously, as a result of an improved selection algorithm that more accurately predicts the patients who would benef...
Europe has 150,000 new head & neck cancer cases each year, more than twice the incidence in the U.S. CEL-SCI Corporation (NYSE American: CVM) today reported it has filed a request for Scientific Advice regarding Multikine* (Leukocyte Interleukin, Injection) immunotherapy for t...
2023-08-11 08:47:18 ET Cel-Sci press release ( NYSE: CVM ): Q2 GAAP EPS of -$0.19. For further details see: Cel-Sci GAAP EPS of -$0.57
News, Short Squeeze, Breakout and More Instantly...
CEL-SCI Corporation (NYSE American: CVM) today announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. Wi...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...